Interferon alpha (IFNa) is involved in the pathogenesis of systemic lupus erythematosus
(SLE)and IFNa levels are associated with the severity of the disease. Blocking IFNa could be
an attractive therapeutic strategy. Active immunization with IFNa kinoid (IFN-K) induces a
polyclonal antibody response.
This study will evaluate the safety of IFN-K in patients with mild to moderate SLE. It will
also measure the induction of anti-IFNa antibodies and evaluate the clinical impact on SLE